Aerie Pharmaceuticals Inc (NASDAQ:AERI) price target set to $80.00 by JMP Securities

ME Staff
-
0

Analyst Ratings For Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Today, JMP Securities set its price target on Aerie Pharmaceuticals Inc (NASDAQ:AERI) to $80.00 per share.

There are 10 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) is Buy with a consensus target price of $84.30 per share, a potential 59.48% upside.

Some recent analyst ratings include

  • 10/2/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Cantor Fitzgerald with a $86.00 price target
  • 8/10/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Canaccord Genuity with a $86.00 price target

Recent Insider Trading Activity For Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals Inc (NASDAQ:AERI) has insider ownership of 10.53% and institutional ownership of 95.99%.

  • On 10/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.56 per share and the total transaction amounting to $666,160.00.
  • On 9/27/2018 Richard J Rubino, CFO, sold 66,605 with an average share price of $60.23 per share and the total transaction amounting to $4,011,619.15.
  • On 9/13/2018 Richard J Rubino, CFO, sold 34,512 with an average share price of $60.17 per share and the total transaction amounting to $2,076,587.04.
  • On 9/4/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.09 per share and the total transaction amounting to $660,990.00.
  • On 8/27/2018 Thomas A Mitro, COO, sold 190,000 with an average share price of $60.27 per share and the total transaction amounting to $11,451,300.00.
  • On 8/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $68.30 per share and the total transaction amounting to $751,300.00.
  • On 7/2/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $66.37 per share and the total transaction amounting to $730,070.00.

About Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Recent Trading Activity for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals Inc closed the previous trading session at 53,02 −0,19 0,36 % with shares trading hands.